Age related bowel problems, erectile dysfunction

The curious thing here is the word normal. It’s being used in this context to mean age-related. Most men in the sample didn’t have erectile dysfunction. But because ED’s frequency increases with age, and because we think of aging as a universal process accompanied by physical decline, ED seems normal.

Since “urinary and bowel dysfunction were not part of the ‘normal’ aging process,” the authors conclude, they “may well be related to prior treatment” in men who have been treated for prostate cancer. This appears to make them logical targets for prevention or remedy. Does the opposite implication follow for ED? Does its “normality” make it a less compelling target?

There are many plausible ways to think about normality and health. Age-dependence is one of them. To me, the authors’ framework makes sense: Medicine should focus first on maladies that strike some people unusually early in life. Maladies that accumulate with age are less unfair. They’re also less tractable, since they’re more biologically inherent.

ED, however, is a confounding example because it’s in the process of being transformed from a “normal” to a commonly treated condition. Bob Dole made his famous ad for Viagra in 1999, when he was 76. In the last decade, 35 million men have used Viagra. Millions more have taken similar drugs such as Cialis or Levitra. Modern man has set out to conquer the ancient loss of manhood.
Which brings us back to the question posed in Urology: Does normal aging imply ED? The answer seems to be: It used to. And that’s not just a change in the way we think about erections. It’s a change in the way we think about aging.

Norvir tablet will not require refrigeration

The heat-stable Norvir tablet will not require refrigeration, making it more convenient for patients to use, particularly in developing countries where the majority of people with HIV live.
“The heat-stable formulation of ritonavir may help to further expand protease inhibitor-based HAART (highly active antiretroviral therapy) in regions where the need for refrigeration of HIV medicines is a major barrier to treatment and care,” said Pedro Cahn, M.D., Ph.D., president, International AIDS Society.
The study compared the bioavailability of the 100mg ritonavir tablet to that of a 100mg soft-gelatin capsule under non-fasting conditions. The ritonavir tablet demonstrated similar bioavailability to the current soft- gelatin capsule, and was generally well tolerated. In this study performed in 93 healthy adult volunteers, the safety profiles of the two formulations were similar, with no serious adverse events reported.
Several formulations were evaluated, and the final formulation evaluated in the bioavailability study is the product of significant testing and formulation work. The data presented are the basis of upcoming regulatory submissions.
Abbott has confirmed its intention to submit registration applications for the tablet and request priority review by U.S. and EU authorities before the end of the year.
Abbott intends to register the new Norvir tablet as broadly worldwide as lopinavir/ritonavir, the most widely registered PI worldwide, according to the World Health Organization. The lopinavir/ritonavir tablet is approved for sale, available (in countries where no regulatory approval is needed), or has been submitted for registration in 157 countries around the world.
The Norvir tablet was developed using the Meltrex(R) technology, which was also used in the development of Abbott’s Kaletra(R) tablets, which combine ritonavir and lopinavir. However, ritonavir on its own required a different formulation to ensure that the tablets remain stable over time and that the body can absorb the drug.
About Abbott’s Commitment to Fighting HIV/AIDS
HIV/AIDS is a global problem that demands shared commitment and shared responsibility. Abbott is committed to working with governments, multilateral organizations, nongovernmental organizations and patient groups to expand access to HIV treatments around the world. Abbott has also made significant investments in expanding manufacturing capacity to meet the growing demand for HIV treatment in developing countries.
Abbott’s lopinavir/ritonavir formulations are among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicines at a price of US$500 per adult patient per year in all African and least developed countries since 2002, making these medicines more affordable than any generic copies.
Abbott and the company’s philanthropic foundation, Abbott Fund, have invested more than US$100 million in the fight against HIV/AIDS in Africa and the developing world. Abbott Fund-supported programs have served more than 700,000 children and families. In addition, more than 250,000 patients have been tested through Abbott Fund-supported voluntary counseling and testing programs, with thousands being referred to treatment programs. Abbott also has donated more than eight million rapid HIV tests to help prevent mother-to- child HIV transmission.
Abbott and Abbott Fund have announced several efforts to expand access to treatment and care for children living with HIV/AIDS, including an additional investment of US$12 million in grants and product donations this year.
For more information about Abbott’s commitment to fighting HIV/AIDS, please visit http://www.abbott.com/hiv.
About Norvir
Indication
NORVIR (ritonavir) is a class of medicines called HIV protease (PRO-tee-ase) inhibitors. NORVIR is used in combination with other anti-HIV medicines to treat people with human immunodeficiency virus (HIV) infection. NORVIR is for adults and for children age one month and older.
Important Safety Information
NORVIR does not cure HIV infection or AIDS and does not reduce the risk of passing HIV to others.
NORVIR must not be taken in patients who have had a serious allergic reaction to NORVIR or any of its ingredients.
Taking NORVIR with certain medicines can cause serious or life-threatening problems such as irregular heartbeat, breathing difficulties or excessive sleepiness. Norvir must not be taken with Cordarone(R) (amiodarone); ergotamine, ergonovine, methylergonovine, and dihydroergotamines such as Cafergot(R); Migranal(R); D.H.E. 45(R) and others; Halcion(R) (triazolam); Hismanal(R) (astemizole); Orap(R) (pimozide); Propulsid(R) (cisapride); Quinidine(R), also known as Quinaglute(R); Cardioquin(R); Quinidex(R); Rythmol(R) (propafenone); Seldane(R) (terfenadine); Tambocor(R); (flecainide); Uroxatral(R) (alfuzosin hydrochloride); Vascor(R) (bepridil); Versed(R) (midazolam); and Vfend(R) (voriconazole).
NORVIR must not be taken with St. John’s Wort (hypericum perforatum), Mevacor(R) (lovastatin) or Zocor(R) (simvastatin).
There are drug-drug interactions with the potential for risk of serious or life-threatening side effects. Alterations in dose, increased monitoring of drug levels in the blood or increased observations for side effects may be recommended when NORVIR is taken with: Lipitor(R) (atorvastatin), Crestor(R) (rosuvastatin), Viagra(R) (sildenafil), Cialis(R) (tadalafil), Levitra(R) (vardenafil), oral contraceptives (”the pill”) or the contraceptive patch, Mycobutin(R) (rifabutin), rifampin, also known as Rimactane(R), Rifadin(R), Rifater(R) or Rifamate(R); inhaled Flonase(R) (fluticasone), metronidazole or disulfiram.
Rifampin and saquinavir should not be taken together with NORVIR. Patients should tell their doctor if they are taking rifampin and saquinavir.
The above lists of medicines are not complete. Patients should discuss all medicines, including those without a prescription and herbal preparations they are taking or plan to take, with their doctor or pharmacist.
The most commonly reported side effects are: feeling weak or tired, nausea, vomiting, diarrhea, loss of appetite, abdominal pain, changes in taste, tingling feeling or numbness in hands or feet or around the lips, headache, and dizziness. This is not a complete list of reported side effects.
Pancreatitis and liver problems, which can be fatal, have been reported in patients receiving NORVIR. Patients should tell their doctor if they have nausea, vomiting, or abdominal pain, which may be signs of pancreatitis, or if they have or have had liver disease such as Hepatitis B or C.
Some patients have had large increases in triglycerides and cholesterol. Changes in body fat have been seen in some patients taking anti-HIV therapy. The long-term health effects of these conditions are not known at this time.
Diabetes and high blood sugar have occurred in patients taking protease inhibitors, such as NORVIR.
Some patients with hemophilia have increased bleeding with protease inhibitors.
The effects of NORVIR on pregnant women or to their unborn babies are not known. Mothers taking NORVIR should not breastfeed.
Refrigeration of NORVIR soft gelatin capsules by the patient is recommended, but not required if used within 30 days and stored below 77 degrees F (25 degrees C). Avoid exposing NORVIR soft gelatin capsules to excessive heat or cold. Store in the original container.
Store NORVIR oral solution at room temperature. Do not refrigerate NORVIR oral solution. Avoid exposing NORVIR oral solution to excessive heat or cold. Store in the original container.
About Kaletra
Indication
KALETRA (lopinavir/ritonavir) is a human immunodeficiency virus-1 (HIV-1) protease inhibitor. KALETRA is always used in combination with other anti-HIV-1 medicines for the treatment of HIV-1 infection. KALETRA is a combination of two medicines, lopinavir and ritonavir. KALETRA is for adults and for children age six months and older.
Source: http://www.marketwatch.com/news/story/abbott-study-shows-investigational-heat-stable/story.aspx?guid=%7B4A12C043-B55C-4A91-9875-EF2218D60F8F%7D&dist=hppr

The FDA has approved Eli Lilly’s oral medication cialis 2.5mg and 5mg

The company said that when cealis for once-daily use is taken daily, men can attempt sexual activity at anytime between doses. Currently available in parts of Europe, this low-dose daily treatment option of cealis may be most appropriate for men with erectile dysfunction who anticipate more frequent sexual activity (e.g. twice weekly). In clinical trials, when taken without restrictions on the timing of sexual activity, Cialis for once-daily use improved erectile function over the course of therapy.

Shawn Heffern, Cialis US director of brand marketing at Lilly, said: “We strive to provide patients with solutions that fit their needs and Cialis for once-daily use delivers on this promise. Now, patients have two options, some may prefer the up to 36 hours of efficacy provided by Cialis for use as needed while others may want the unique benefit provided by this daily dosing option.” More….